Lazertinib

Major

Lazertinib Clindamycin ANTIROBE Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Colchicine Colcrys Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Abemaciclib Verzenio Explained Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Acalabrutinib Calquence Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Lazertinib Axitinib Inlyta Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Bosutinib Bosulif Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Brigatinib Alunbrig Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Clindamycin Injection ANTIROBE Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Clindamycin Topical C/T/S® Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Clindamycin Vaginal Cleocin Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Cobimetinib Cotellic Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Cyclosporine Injection Atopica Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Cyclosporine Ophthalmic Cequa Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Dasatinib Phyrago Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Dexamethasone Injection Decadron Reduced lazertinib exposure and reduced efficacy of lazertinib Details Lazertinib Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced lazertinib exposure and reduced efficacy of lazertinib Details Lazertinib Dihydroergotamine Injection DHE-45® Injection Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Dihydroergotamine Nasal Spray Migranal Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Docetaxel Beizray Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Docetaxel Injection Beizray Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Dofetilide Tikosyn Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Encorafenib Braftovi Reduced lazertinib exposure and reduced efficacy of lazertinib Details Lazertinib Entrectinib Rozlytrek Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Everolimus Afinitor Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Fentanyl Transdermal Patch Duragesic® Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Lazertinib Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Lazertinib Methylergonovine Methergine Increased methylergonovine exposure Details Lazertinib Midostaurin Rydapt Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Mitapivat Aqvesme Reduced lazertinib exposure and reduced efficacy of lazertinib Details Lazertinib Nafcillin Injection Unipen® Injection Reduced lazertinib exposure and reduced efficacy of lazertinib Details Lazertinib Neratinib Nerlynx Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Lazertinib Nifedipine Adalat® Increased NIFEdipine exposure Details Lazertinib Olaparib Lynparza Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details